From Financial Modeling Prep: 2024-11-06 20:00:03

In summary, Jazz Pharmaceuticals, a biopharmaceutical company, reported an EPS of $3.40, below the estimated $5.50, but achieved third-quarter revenue of $1.05 billion, exceeding expectations. The company’s product pipeline includes a PDUFA date for Zanidatamab and plans for a supplemental New Drug Application for Zepzelca, demonstrating a strategic focus on oncology. With strong financials and market valuation metrics, Jazz is well-positioned for future growth.



Read more at Financial Modeling Prep:: Jazz Pharmaceuticals’ Financial and Operational Hi…